KLH conjugated synthetic peptide derived from human CXCR5
Purified by Protein A.
0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Cytokine receptor that binds to B-lymphocyte chemoattractant (BLC). Involved in B-cell migration into B-cell follicles of spleen and Peyer patches but not into those of mesenteric or peripheral lymph nodes. May have a regulatory function in Burkitt lymphoma (BL) lymphomagenesis and/or B-cell differentiation.
PRODUCT SPECIFIC PUBLICATIONS
- Huang, Hu, et al. "Age-related macular degeneration phenotypes are associated with increased tumor necrosis-alpha and subretinal immune cells in aged Cxcr5 knockout mice." PloS one 12.3 (2017): e0173716.Read more>>
- Gong, Qiaoqiao, et al. "Increased levels of CCR7 (lo) PD‑1 (hi) CXCR5+ CD4+ T cells, and associated factors Bcl‑6, CXCR5, IL‑21 and IL‑6 contribute to repeated implantation failure." Experimental and Therapeutic Medicine 14.6 (2017): 5931-5941.Read more>>
- Gong et al. Increased levels of CCR7(lo)PD-1(hi) CXCR5+CD4+T cells, and associated factors Bcl-6, CXCR5, IL-21 and IL-6 contribute to repeated implantation failure. (2017) Exp.Ther.Med. 14:5931-5941Read more>>
Lane 1: Mouse lymph node lysates probed with CXCR5 Polyclonal Antibody, Unconjugated (bs-3598R) at 1:300 overnight at 4˚C. Followed by a conjugated secondary antibody at 1:5000 for 90 min at 37˚C.
Lane 1: Raji cell lysates; Lane 2: Mouse Lymph node lysates probed with CXCR5 Polyclonal Antibody, Unconjugated (bs-3598R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.